Westfield Capital Management
LGND icon

Westfield Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Westfield Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,900
Closed -$294K – 337
2013
Q3 		$294K Hold
10,900
– – ﹤0.01% 329
2013
Q2 		$254K Buy
+10,900
New +$196K ﹤0.01% 338

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Westfield Capital Management's LGND Position: Q4 2013 in Review

Westfield Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2013, closing a stake of 10,900 shares — an estimated $294K sold.

Westfield Capital Management first reported a position in LGND in Q2 2013 and held it in 2 quarters. The position peaked at $294K in Q3 2013. 165 funds tracked by Wall St. Rank hold LGND as of Q4 2013.

  • Westfield Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Westfield Capital Management sold 10,900 Ligand Pharmaceuticals shares in Q4 2013, an estimated $294K.
  • Westfield Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Westfield Capital Management's Ligand Pharmaceuticals position peaked at $294K in Q3 2013.
  • 165 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2013.

Based on Westfield Capital Management's 13F filing for Q4 2013, filed 7 Feb 2014.